Four years ago, ImmunoGen (IMGN) marked a significant achievement in the Waltham, Mass., company’s history with the market debut of Kadcyla, a breast cancer drug that uses innovative biotechnology to target cancer while sparing healthy cells.
The Genentech division of Swiss drug giant Roche won approval from U.S. and European regulators to sell Kadcyla, but the “payload platform” that enables the drug to bind to tumors was painstakingly developed over three decades by ImmunoGen.
